The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | New therapeutic standard for AML in remission: QUAZAR
Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, discusses the primary results of QUAZAR AML-001 (NCT01757535), a phase 3 international, randomized, double-blind, placebo-controlled study evaluating an oral formulation of azacitidine (CC-486) as a maintenance therapy in older patients with acute myeloid leukemia (AML) in first remission following induction chemotherapy. Studies performed demonstrated that CC-486 has a manageable safety profile and represents a new therapeutic standard for patients with AML in remission. This interview was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
